Examining the immune response in sentinel lymph nodes of mice and men

European Journal of Nuclear Medicine

Volumn 26, Issue SUPPL., 1999, Pages

  Chu, Y ^a   Hu, H M ^a,b   Winter, H ^a   Wood, W J ^a   Doran, T ^a   Lashley, D ^a,c   Bashey, J ^a,c   Schuster, J ^a   Wood, J ^a   Lowe, B A ^b,c   Vetto, J T ^b,c   Weinberg, A D ^a,b,c   Puri, R ^d   Smith II, J W ^a,b   Urba, W J ^a,b   Fox, B A ^a,b,c  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Immune deviation; Immunological monitoring; Sentinel lymph nodes; Tumor vaccine draining lymph nodes; Tumor vaccines

Indexed keywords

TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL MODEL; ANTIGEN PRESENTATION; BREAST CANCER; CONFERENCE PAPER; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; LYMPH NODE; LYMPHATIC DRAINAGE; MELANOMA; MOUSE; NONHUMAN; TUMOR IMMUNITY;

ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HUMANS; KIDNEY NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MICE;

EID: 6544229087     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050578     Document Type: Conference Paper

References (13)

1. Hu H-M. Urba WJ, Fox BA. Gene modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to type 1 cytokine profile. J Immunol 1998: 161: 3033-3041.
2. Bradley LM, Duncan DD, Tonkonogy S, Swain SL. Characterization of antigen-specific CD4+ effector T cells in vivo: immunization results in a transient population of MEL-14-. CD45RB- helper cells that secretes interleukin 2 (1L-2), IL-3, IL-4, and Interferon gamma. J Exp Med 1991; 174: 547-559.
3. Kagamu H, Touhalisky J, Plantz G, Krauss J, Shu S. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Rex 1996; 56: 4338-4342.
4. Rocken M, Shevach EM. Immune deviation - the third dimension of nondeletional T cell tolerance. Immunol Rev 1996; 149: 175-194.
5. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11: 191-212.
6. Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CDS effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type I cytokine profiles. J Exp Med 1994; 180: 1715-1728.
7. Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and IL-2. J Clin Oncol 1997; 15: 796-807.
8. Winter H, Fox BA, Adoptive cellular immunotherapy of cancer. Curr Opin Mol Ther, 1991; 1: 89-97.
9. Kanegane H, Kasahara Y, Niida Y, Yachie A, Sughii S, Takatsu K, Taniguchi N, Miyawaki T. Expression of L-selectin (CD62L) discriminates Th1- and Th2-like cytokine-producing memory CD4+ T cells. Immunology 1996; 87: 186-190.
10. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA. IL-12 induces T helper 1-directed antitumor response. J Immunol 1997; 158: 3359-3365.
11. Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE. Type 1 vs type 2 cytokine release by Vb T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 1997; 159: 664-673.
12. Lowes MA, Bishop GA, Crotty K, Barnetson RS, HGM. T helper I cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 1997; 108: 914-919.
13. Clerici M, Shearer GM, Clerici E, Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J Natl Cancer Inst 1998; 90: 261